A Randomized, Controlled, Observer-blind Psoriasis Plaque Test to Investigate the Anti-psoriatic Efficacy, Tolerability and Safety (Skin Atrophy) of LAS41004 Formulations in Patients With Mild to Moderate Plaque Psoriasis
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 18
- 试验地点
- 1
- 主要终点
- Area under the curve, AUC, of the width of the echo-lucent band based on sonography measurements
研究概览
简要总结
Clinical investigation of anti-psoriatic efficacy and atrophy
详细描述
In this trial three concentrations of bexarotene in combination with a fixed concentration of betamethasone dipropionate, as well as monotherapy with bexarotene, will be investigated regarding their efficacy, tolerability and safety in patients with mild to moderate plaque psoriasis and will be compared with the vehicle and an active comparator.
Since a side effect of the application of corticosteroids is skin atrophy, additionally three non-lesional test areas (not affected by psoriasis) on the volar forearm will be treated with the active reference product, one of the fixed combinations and the vehicle. Skin atrophy will be investigated by visual assessment and ultrasound at these test areas
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •18 to 75 years of age
- •Men and women with skin type I to IV (Fitzpatrick 1974).
- •Suffering from mild to moderate plaque psoriasis of at least 6 months duration that is amenable to local therapy.
- •With at least one stable psoriatic plaque in an area sufficient for product application meeting the following criteria:
- •Located at the trunk and/or the extremities (plaques located on the head, palms, or soles of the feet, intertriginous or genitoanal areas are not suitable).
- •Plaques with a clinical score of the parameter erythema and or induration of ≥ 2 for each sign at the screening visit. At Day 1 each parameter has to be scored ≥
- •Where more than one plaque is to be used, plaques should be comparable, with at least "2" in each score for erythema and induration.
- •• Body surface area (BSA) involvement < 10 %.
- •Prepared to give written informed consent specific to the trial, before any assessment is performed.
- •• In the case of women of childbearing potential using reliable methods of contraception which result in a low failure rate i.e. less than 1% per year (e.g. contraceptive implants or injectables, combined oral contraceptives, some intrauterine devices, sexual abstinence or vasectomized partner). During the study an additional barrier method (e.g. condoms) should be used. Non-childbearing potential is defined as surgical sterilization (hysterectomy, ovariectomy or tubal ligation), postmenopausal status (continuous amenorrhea of at least 2 years).
- •In the case of men with partners of childbearing potential willingness of using condoms during the study conduct and 1 month after end of treatment.
排除标准
- •• Patients who need systemic treatment for their psoriasis.
- •Severe forms of psoriasis or forms of psoriasis other than chronic plaque psoriasis,
- •Systemic treatment (see table below):
- •Corticosteroids, antibiotics 4 weeks prior to trial Day 1 and during conduct of trial Retinoids Ciclosporin Methotrexate Fumaric acid esters 3 months prior to trial Day 1 and during conduct of trial Anti-inflammatory substances, NSAIDs 2 weeks prior to trial Day 1 and during conduct of trial Biologics 6 months prior to trial Day 1 and during conduct of trial
- •Topical treatment of all other body regions with corticosteroids or immunosuppressants where more than 20 % of the body surface area is treated.
- •Diseases:
- •Significant skin infections caused by bacteria, viruses or fungi, including but not limited to tuberculosis, syphilis or varicella zoster infection Parasitic infections
研究组 & 干预措施
formulation 1
topical treatment, once daily for 4 weeks
干预措施: LAS41004-IMP1 (Drug)
formulation 1
topical treatment, once daily for 4 weeks
干预措施: LAS41004 IMP2 (Drug)
formulation 1
topical treatment, once daily for 4 weeks
干预措施: LAS41004 IMP3 (Drug)
formulation 1
topical treatment, once daily for 4 weeks
干预措施: LAS41004 IMP4 (Drug)
formulation 1
topical treatment, once daily for 4 weeks
干预措施: LAS41004 IMP6 (Drug)
formulation 1
topical treatment, once daily for 4 weeks
干预措施: LAS41004 IMP5 (Drug)
formulation 2
topical treatment, once daily for 4 weeks
干预措施: LAS41004-IMP1 (Drug)
formulation 2
topical treatment, once daily for 4 weeks
干预措施: LAS41004 IMP2 (Drug)
formulation 2
topical treatment, once daily for 4 weeks
干预措施: LAS41004 IMP3 (Drug)
formulation 2
topical treatment, once daily for 4 weeks
干预措施: LAS41004 IMP4 (Drug)
formulation 2
topical treatment, once daily for 4 weeks
干预措施: LAS41004 IMP6 (Drug)
formulation 3
topical treatment, once daily for 4 weeks
干预措施: LAS41004 IMP3 (Drug)
formulation 3
topical treatment, once daily for 4 weeks
干预措施: LAS41004 IMP4 (Drug)
formulation 6
topical treatment, once daily for 4 weeks
干预措施: LAS41004-IMP1 (Drug)
formulation 6
topical treatment, once daily for 4 weeks
干预措施: LAS41004 IMP2 (Drug)
formulation 6
topical treatment, once daily for 4 weeks
干预措施: LAS41004 IMP3 (Drug)
formulation 6
topical treatment, once daily for 4 weeks
干预措施: LAS41004 IMP4 (Drug)
formulation 6
topical treatment, once daily for 4 weeks
干预措施: LAS41004 IMP6 (Drug)
formulation 6
topical treatment, once daily for 4 weeks
干预措施: LAS41004 IMP5 (Drug)
formulation 3
topical treatment, once daily for 4 weeks
干预措施: LAS41004 IMP6 (Drug)
formulation 3
topical treatment, once daily for 4 weeks
干预措施: LAS41004 IMP5 (Drug)
formulation 4
topical treatment,once daily for 4 weeks
干预措施: LAS41004-IMP1 (Drug)
formulation 4
topical treatment,once daily for 4 weeks
干预措施: LAS41004 IMP2 (Drug)
formulation 4
topical treatment,once daily for 4 weeks
干预措施: LAS41004 IMP3 (Drug)
formulation 4
topical treatment,once daily for 4 weeks
干预措施: LAS41004 IMP4 (Drug)
formulation 4
topical treatment,once daily for 4 weeks
干预措施: LAS41004 IMP6 (Drug)
formulation 4
topical treatment,once daily for 4 weeks
干预措施: LAS41004 IMP5 (Drug)
formulation 5
topical treatment, once daily for 4 weeks
干预措施: LAS41004 IMP2 (Drug)
formulation 5
topical treatment, once daily for 4 weeks
干预措施: LAS41004 IMP3 (Drug)
formulation 5
topical treatment, once daily for 4 weeks
干预措施: LAS41004 IMP4 (Drug)
formulation 5
topical treatment, once daily for 4 weeks
干预措施: LAS41004 IMP6 (Drug)
formulation 5
topical treatment, once daily for 4 weeks
干预措施: LAS41004-IMP1 (Drug)
formulation 2
topical treatment, once daily for 4 weeks
干预措施: LAS41004 IMP5 (Drug)
formulation 3
topical treatment, once daily for 4 weeks
干预措施: LAS41004-IMP1 (Drug)
formulation 3
topical treatment, once daily for 4 weeks
干预措施: LAS41004 IMP2 (Drug)
formulation 5
topical treatment, once daily for 4 weeks
干预措施: LAS41004 IMP5 (Drug)
结局指标
主要结局
Area under the curve, AUC, of the width of the echo-lucent band based on sonography measurements
时间窗: day 1 vs day 29
The primary objective is to gain evidence suggesting efficacy of the investigational products in the treatment of plaque-type psoriasis as assessed by the AUC of the width of the echo-lucent band
次要结局
- erythema and induration(day 1 vs day 29)
- local skin tolerability(every day for 28 days)
- atrophy(day1 vs day 29)
- assessment of (serious) Adverse Events(from baseline to day 29)